We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01246375
Recruitment Status : Unknown
Verified November 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : November 23, 2010
Last Update Posted : November 25, 2010
Information provided by:

November 21, 2010
November 23, 2010
November 25, 2010
December 2010
December 2011   (Final data collection date for primary outcome measure)
  • Diagnosis of Osteoporosis [ Time Frame: 3 month ]
  • Diagnosis of Osteoporosis [ Time Frame: 3 ]
  • Diagnose of osteoporosis [ Time Frame: 3 month ]
  • Diagnose of Osteoperosis [ Time Frame: 3 ]
Complete list of historical versions of study NCT01246375 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids
Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids
The purpose of this research is to determine whether the prevalence of osteoporosis is greater in patients who suffer from Chronic obstructive pulmonary disease (COPD) or Asthma disease and uses inhaled steroids.
Not Provided
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Device: Dual energy X-ray absorptiometry
Device which measures bone density
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
December 2011
December 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Man at the minimum age of 60 years.
  2. Diagnosed with Chronic Obstructive Pulmonary disease (COPD) or Asthma disease.
  3. Usage of the following corticosteroids at the minimal doses indicated, for at least 3 years:

Seretide 250/50 mcg Symbicort 320/9 mcg 5.No Diagnosis of thyroid irregularity 6.No diagnosis/treatment for Osteoporosis.

Exclusion Criteria:

  1. Usage of systemic steroids more than once during the 12 months prior to the study.
  2. Usage of systemic steroids during the month prior to the study.
  3. Usage of inhaled steroids in order to treat any other disease except Chronic Obstructive Pulmonary Disease (COPD) or Asthma.
Sexes Eligible for Study: Male
60 Years to 90 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Dr. Yehuda Schwartz, Tel Aviv medical center
Tel-Aviv Sourasky Medical Center
Not Provided
Principal Investigator: Yehuda Schwartz, M.D Tel Aviv Medical Center
Tel-Aviv Sourasky Medical Center
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP